Sarilumab, Tocilizumab, and siltuximab are existing FDA-approved IL-6 inhibitors for rheumatoid arthritis and COVID-19 to reduce damages caused by IL-6-induced inflammation [94,95]. This evidence concerns the gene IL6 and rheumatoid arthritis.